Valoración de la marcha mediante plantillas instrumentadas en pacientes con espasticidad de miembros inferiores tras infiltración con toxina botulínica

Béseler, M.R.; Grao, C.M.; Gil, Andrzej; Lozano, María Eugenia Martínez

doi:10.1016/j.nrl.2011.07.007

Cited by 8 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this connection, mention should be made of the series reported by Hecht et al, 39 who describe 19 injected cases of familial spastic paraparesis (FSP), with improvement and sideeffects, such as weakness in 4 cases and pain in 1, bearing in mind here that, in this type of lesion, the spastic pattern is flexor of the lower extremities. Other series with fewer cases were those reported by Bohlega 40 (which used a BoNT unavailable in Spain) and by Beseler, 41 which included 2 cases with other disorders.…”

Section: Discussionmentioning

confidence: 98%

Treatment of spasticity in spinal cord injury with botulinum toxin

Palazón-García

Alcobendas-Maestro

Ruz

et al. 2018

The Journal of Spinal Cord Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Treatment of spasticity in spinal cord injury with botulinum toxin

Palazón-García

Alcobendas-Maestro

Ruz

et al. 2018

The Journal of Spinal Cord Medicine

View full text Add to dashboard Cite

show abstract

“…Bermuz et al studied 15 people with incomplete SCI and the effect of injecting 200 U of ONA into the rectus femoris measured with isokinetics muscle testing, reporting only general improvement without specifying details [ 62 ]. Other case series included spasticity of various etiologies with very small sample sizes [ 63 , 64 ], and the rest of the articles published include only isolated cases [ 65 , 66 , 67 , 68 ]. There are only a very few studies that have characterized the effect of BoNT treatment on SCI spasticity, and, therefore, well-developed clinical guidelines cannot be proposed based on strong evidence.…”

Section: Treatment Of Spasticity In Spinal Cord Injury With Botulinum Toxinmentioning

confidence: 99%

Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury

Palazón-García

Benavente-Valdepeñas

2021

IJMS

View full text Add to dashboard Cite

Botulism has been known for about three centuries, and since its discovery, botulinum toxin has been considered one of the most powerful toxins. However, throughout the 20th century, several medical applications have been discovered, among which the treatment of spasticity stands out. Botulinum toxin is the only pharmacological treatment recommended for spasticity of strokes and cerebral palsy. Although its use as an adjuvant treatment against spasticity in spinal cord injuries is not even approved, botulinum toxin is being used against such injuries. This article describes the advances that have been made throughout history leading to the therapeutic use of botulinum toxin and, in particular, its application to the treatment of spasticity in spinal cord injury.

show abstract

The Effect of Repeated abobotulinumtoxinA (Dysport®) Injections on Walking Velocity in Persons with Spastic Hemiparesis Caused by Stroke or Traumatic Brain Injury

Esquenazi

Brashear

Deltombe

et al. 2020

PM&R

View full text Add to dashboard Cite

Background Botulinum toxin (BoNT) injections were shown to improve muscle tone of limbs in patients with spasticity. However, limited data are available regarding the effects of repeated BoNT injections on walking ability. Objective To assess changes in walking velocity (WV), step length, and cadence under different test conditions after repeated treatment with abobotulinumtoxinA (aboBoNT‐A; Dysport) in spastic lower limb muscles. Design Secondary analysis of an open‐label, multiple‐cycle extension (National Clinical Trials number NCT01251367) to a phase III, double‐blind, randomized, placebo‐controlled, single‐treatment cycle study, in adults with chronic hemiparesis (NCT01249404). Setting Fifty‐two centers across Australia, Belgium, the Czech Republic, France, Hungary, Italy, Poland, Portugal, Russia, Slovakia, and the United States. Patients 352 Ambulatory adults (18‐80 years) with spastic hemiparesis and gait dysfunction caused by stroke or traumatic brain injury, with a comfortable barefoot WV of 0.1 to 0.8 m/s. Interventions Up to four aboBoNT‐A treatment cycles, administered to spastic lower limb muscles. Main Outcome Measurements Changes from baseline in comfortable and maximal barefoot and with shoes WV (m/s), step length (m/step), and cadence (steps/minutes). Results At Week 12 after four injections, WV improved by 0.08 to 0.10 m/s, step length by 0.03 to 0.04 m/step, and cadence by 3.9 to 6.2 steps/minutes depending on test condition (all P < .0001 to .0003 vs baseline). More patients (7% to 17%) became unlimited community ambulators (WV ≥0.8 m/s) across test conditions compared with baseline, with 39% of 151 patients classified as unlimited community ambulators in at least one test condition and 17% in all four test conditions. Conclusions Clinically meaningful and statistically significant improvements in WV, step length, and cadence under all four test conditions were observed in patients with spastic hemiparesis after each aboBoNT‐A treatment cycle.

show abstract

Valoración de la marcha mediante plantillas instrumentadas en pacientes con espasticidad de miembros inferiores tras infiltración con toxina botulínica

Cited by 8 publications

References 17 publications

Treatment of spasticity in spinal cord injury with botulinum toxin

Treatment of spasticity in spinal cord injury with botulinum toxin

Botulinum Toxin: From Poison to Possible Treatment for Spasticity in Spinal Cord Injury

The Effect of Repeated abobotulinumtoxinA (Dysport®) Injections on Walking Velocity in Persons with Spastic Hemiparesis Caused by Stroke or Traumatic Brain Injury

Contact Info

Product

Resources

About